//Vivian Liu, Head of Corporate Affairs (left), and Eileen Kuida, Controller (right)
Eileen has over 25 years of comprehensive experience in multi-country finance and operations leadership, including M&As, financial planning, analysis/reporting, and SOX compliance. Eileen holds an MBA from the University of Southern California and a BA from UC Berkeley.
Head of Corporate Affairs
Vivian has over 20 years in operating and financing pharmaceutical companies, including C-level and Board of Directors positions at several private and Nasdaq companies. Vivian holds an MPA from the University of Southern California and a BA from UC Berkeley.
Genevieve Chase, PhD
Director of Asia Pacific Expansion
and Alliance Management
Genevieve completed her Bachelor of Science (1st Class Honours) and PhD in Chemistry, at the University of Sydney, Australia, developing platinum-based chemotherapeutics. Following her post-doctoral research at Virginia Commonwealth University, USA, Genevieve moved to Asia, first volunteering and fundraising in Thailand for nine months before moving to Singapore.
In her 14 years supporting clients in Asia, Genevieve has gained experience spanning medical writing, project management and supervision, protocol development, content strategy, and development of international programmes. Highlights of her career include developing and leading the ACT China programme (to teach oncologists how to write clinical trial protocols and conduct clinical trials), as well as developing recommendations for vaccination, women’s health, and the management of cancer pain.
Throughout Genevieve’s career, she has shown a flare and passion for working with medical experts. She loves providing new avenues for healthcare education, challenging the ways that medical education is conducted to ensure her audience gains that “A-HA!” moment.
At PREMIA, Genevieve leads the expansion of our activities in south-east Asia, and manages our diagnostic development outside of Japan.
Takashi Seto, MD
Head of Medical Affairs
Dr. Seto has over 25 years of experience in oncology research specializing in medical oncology for thoracic malignancies. Conducting clinical trials with new agents has been his primary focus for the past 15 years at the National Kyushu
Cancer Center. His tenure also includes Kumamoto Regional Medical Center and Tokai University Hospital. He joined PREMIA in September 2019 to focus on the development of precision medicine and targeted new drug therapies.
Dr. Seto is a member of the International Association for Study of Lung Cancer (IASLC, Board of Directors), the American Society for Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), and the Japan Society of Medical Oncology (JSMO, Councilor), and the Japan Lung Cancer Society (JLCS, Councilor). In 2005, Dr. Seto was involved with the revision of the JLCS Practice Guideline and from 2014 to 2018, served as Chief of Medical Oncology and Multidisciplinary Therapy. He is also an active member of the Japan Clinical Oncology Group (JCOG) and a member and board member of the West Japan Oncology Group (WJOG). Dr. Seto graduated from Kurume University School of Medicine in 1990.
//Tatsuya Ikeda , Managing Partner of PREMIA , discussing project with Dr. Ikeda
Chief Operating Officer, Managing Director, and Head of Japan
Tatsuya has over 20 years of business experience including, tenures at Goldman Sachs, General Electric, and Yamato Capital and Developments. He has extensive knowledge and experience in business strategy, project management, corporate finance and business development, and has successfully created, incubated and grown multiple start-ups in Japan and Asia. He became the president of Precision Medicine Asia Ltd., in 2018 and have led all projects in Japan.
Tatsuya received his MBA from the Stern School of Business at New York University and his Bachelors from Hitotsubashi University in Tokyo.
Wenn Sun, Ph.D.
Founder and President
Wenn founded PREMIA in 2018 in collaboration with LCSCRUM leadership. Previously, Wenn was the Founder and Managing Partner for OxOnc Development, a venture company that, along with Pfizer Oncology, co-developed Xalkori in patients with ROS1 genetic alterations. Wenn was the head of Strategic Alliances for GSK Oncology, and helped build it's alliances with various clinical research networks in the world. She was appointed the Chief Business Development officer at the Lurie Cancer Center of Northwestern University after her post-doctoral fellowship at University of Wisconsin-Madison.
Christer Svedman, MD Ph.D.
Head of Genomic Medicine
Christer built the presence for Genomic Health in Europe with a wide range of studies across key markets to help generate clinically relevant data, as well as data to support reimbursement. He was also responsible for extensive medical education programs across Europe, including a yearly European symposium on genomics in breast, colon and prostate cancer. Christer has over 20 years of pharmaceutical and medical research experience, and received his MD and Ph.D. from Lund University.